[go: up one dir, main page]

WO1997015572A1 - N-oxyde de lubeluzole - Google Patents

N-oxyde de lubeluzole Download PDF

Info

Publication number
WO1997015572A1
WO1997015572A1 PCT/EP1996/004608 EP9604608W WO9715572A1 WO 1997015572 A1 WO1997015572 A1 WO 1997015572A1 EP 9604608 W EP9604608 W EP 9604608W WO 9715572 A1 WO9715572 A1 WO 9715572A1
Authority
WO
WIPO (PCT)
Prior art keywords
oxide
lubeluzole
solution
composition according
neuroprotectant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1996/004608
Other languages
English (en)
Inventor
Raymond Antoine Stokbroekx
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to JP9516279A priority Critical patent/JPH11513699A/ja
Priority to EP96934801A priority patent/EP0843674A1/fr
Priority to IL12308396A priority patent/IL123083A0/xx
Priority to AU72982/96A priority patent/AU7298296A/en
Publication of WO1997015572A1 publication Critical patent/WO1997015572A1/fr
Priority to NO981687A priority patent/NO981687D0/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention is concemed with neuroprotectant N-oxide forms of lubeluzole , compositions containing such N-oxide(s), methods of preparing these and their use as a medicine, in particular in the treatment of conditions involving cerebral hypoxia.
  • Conditions involving cerebral hypoxia comprise stroke, more in particular ischaemic stroke, intracerebral haemorrhage and subarachnoid haemorrhage, and head trauma.
  • the treatment of conditions involving cerebral hypoxia currently consists mainly of neuroprotective and of haematologic therapeutic strategies.
  • Optimal therapies remain to be determined.
  • Such an optimized therapy for the treatment of hypoxia is the subject of the present invention.
  • it concerns providing an N-oxide of lubeluzole, a pharmaceutically acceptable acid addition salt form, a solvate or a stereochemically isomeric form thereof, as a new medicine for the treatment of conditions involving cerebral hypoxia.
  • the product is suitable for intravenous and intradermal administration by infusion which is the most appropriate route of administration for hypoxic patients, and also orally, which route is most suitable for maintenace therapy.
  • infusion which is the most appropriate route of administration for hypoxic patients, and also orally, which route is most suitable for maintenace therapy.
  • N-oxides of lubeluzole are meant to comprise those compounds wherein one or more of the nitrogen atoms are oxidized, in particular those wherein the piperidine nitrogen is oxidized.
  • the present invention is concemed with lubeluzole N-oxide, the cis and trans forms of which are represented by the following formulae :
  • Pharmaceutically acceptable acid addition salts comprise the therapeutically active, non-toxic salt forms obtained by treating a base form with an acid such as, for example, an inorganic acid, e.g. hydrochloric, hydrobromic, sulfuric, nitric, phosphoric acid ; or an organic acid, e.g. acetic, propanoic, hydroxyacetic, lactic, pyruvic, malonic, succinic, maleic, fumaric, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, /?-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic acid.
  • Solvates of lubeluzole N-oxide are, for example hydrates, alcoholates.
  • the cis-oriented N-oxide of lubeluzole is particularly preferred, and the most preferred form thereof is the hemihydrate, i.e. (-)-[cis] lubeluzole N-oxide hemihydrate.
  • the N-oxide(s) of lubeluzole can be prepared following art-known procedures of preparing oxides of nitrogen-containing products. They are conveniently prepared by dissolving lubeluzole in a solvent and adding thereto a sufficient amount of a suitable oxidant.
  • suitable oxidants are hydrogen peroxide, peroxic acids, e.g. m-chloroperbenzoic acid, metal oxides, e.g. NaWO4 and the like.
  • Suitable solvents are, for example, water and halogenated hydrocarbons, in particular dichloromethane.
  • the amounts of each of the ingredients in liquid compositions are expressed as percentages by weight based on the total volume of the formulation, unless otherwise indicated.
  • Amounts in solid preparations are expressed as percentages by weight based on the total weight of the formulation, unless otherwise indicated.
  • compositions of lubeluzole N-oxide suitable as medicaments according to the present invention comprise a pharmaceutically effective amount of active ingredient and one or more pharmaceutically acceptable excipients or carriers as known in the art.
  • the pharmaceutical compositions are adapted for oral or parenteral (including intramuscular, subcutaneous, intradermal and intravenous) administration.
  • the formulations are most conveniently presented in discrete dosage units.
  • the pharmaceutically acceptable carrier for formulating the neuroprotectant lubeluzole N-oxide as an infusion is an aqueous solution (a) comprising water ; an isotonizing agent ; and acid, base or buffer substances sufficient to adjust the pH of the solution in the range of from 2.5 to 3.6.
  • the concentration of lubeluzole N-oxide in the present solutions (a) may range from 0.005% to 5%, preferably from 0.01% to 1%, more preferably from 0.02% to 0.2% and in particular is about 0.05%.
  • the present solutions (a) conveniently comprise from 1 to 10% isotonizing agent.
  • the use of glucose as isotonizing agent has the advantage that very clear solutions are obtained.
  • glucose is used in a concentration from 2 to 10%, most preferably of about 5 % .
  • the solutions (a) further comprise acid and base substances to maintain the pH of the solution in the range from 2.5 to 3.6, preferably in the range from 3.0 to 3.4, most preferably at about 3.2.
  • the pH of the solutions (a) is adjusted by appropriate amounts of hydrochloric acid and sodium hydroxide.
  • the pH may also be adjusted by buffer systems comprising mixtures of appropriate amounts of an acid such as phosphoric, tartaric or citric acid, and a base, in particular sodium hydroxide.
  • a solubilizer may be used.
  • a cyclodextrin (CD) or a derivative thereof may be used.
  • Appropriate cyclodextrin derivatives are ⁇ -, ⁇ -, ⁇ -cyclodextrins or ethers and mixed ethers thereof wherein one or more of the hydroxy groups of the anhydroglucose units of the cyclodextrin are substituted with Cj.galkyl, particularly methyl, ethyl or isopropyl, e.g.
  • ⁇ -cyclodextrin randomly methylated ⁇ -cyclodextrin; hydroxy- Cj- ⁇ alkyl, particularly hydroxyethyl, hydroxypropyl or hydroxy-butyl; carboxy- C ⁇ _6alkyl, particularly carboxymethyl or carboxyethyl; Ci-6alkyl-carbonyl, particularly acetyl; C ⁇ _6alkyloxycarbonylC]_6alkyl or carboxyC ⁇ _6alkyloxy- C ⁇ _6alkyl, particularly carboxymethoxypropyl or carboxyethoxy-propyl; Ci-6alkyl- carbonyloxyCi-6alkyl, particularly 2-acetyloxypropyl.
  • solubilizers are ⁇ -CD, 2,6-dimethyl- ⁇ -CD, randomly methylated ⁇ -cyclo-dextrin, 2-hydroxyethyl- ⁇ -CD, 2-hydroxyethyl- ⁇ -CD, 2-hydroxypropyl- ⁇ -CD and (2-carboxymethoxy)propyl- ⁇ -CD, and in particular 2-hydroxypropyl- ⁇ -CD.
  • mixed ether denotes cyclodextrin derivatives wherein at least two cyclodextrin hydroxy groups are etherified with different groups such as, for example, hydroxypropyl and hydroxyethyl.
  • the average molar substitution is used as a measure of the average number of moles of alkoxy units per mole of anhydroglucose.
  • the M.S.value can be determined by various analytical techniques such as nuclear magnetic resonance (NMR), mass spectrometry (MS) and infrared spectroscopy (IR). Depending on the technique used, slightly different values may be obtained for one given cyclodextrin derivative.
  • NMR nuclear magnetic resonance
  • MS mass spectrometry
  • IR infrared spectroscopy
  • slightly different values may be obtained for one given cyclodextrin derivative.
  • the M.S. as determined by mass spectrometry is in the range of 0.125 to 10, in particular of 0.3 to 3, or from 0.3 to 1.5.
  • D.S. refers to the average number of substituted hydroxyls per anhydroglucose unit.
  • the D.S. value can be determined by various analytical techniques such as nuclear magnetic resonance (NMR), mass spectrometry (MS) and infrared spectroscopy (IR). Depending on the technique used, slightly different values may be obtained for one given cyclodextrin derivative. In the cyclodextrin derivatives for use in the compositions according to the present invention the D.S.
  • D.S. as determined by MS is in the range of 0.125 to 3, in particular of 0.2 to 2 or from 0.2 to 1.5.
  • the D.S. ranges from about 0.2 to about 0.7, in particular from about 0.35 to about 0.5 and most particularly is about 0.4.
  • D.S. values determined by NMR or IR preferably range from 0.3 to 1, in particular from 0.55 to 0.75.
  • ⁇ - and ⁇ -cyclodextrin hydroxyalkyl derivatives for use in the compositions according to the present invention are partially substituted cyclodextrin derivatives wherein the average degree of alkylation at hydroxyl groups of different positions of the anhydroglucose units is about 0% to 20% for the 3 position, 2% to 70% for the 2 position and about 5% to 90% for the 6 position.
  • the amount of unsubstituted ⁇ - or ⁇ -cyclodextrin is less than 5% of the total cyclodextrin content and in particular is less than 1.5%.
  • Another particularly interesting cyclodextrin derivative is randomly methylated ⁇ -cyclodextrin.
  • cyclodextrin derivatives for use in the present invention are those partially substituted ⁇ -cyclodextrin ethers or mixed ethers having hydroxypropyl, hydroxyethyl and in particular 2-hydroxypropyl and/or 2-(l -hydroxypropyl) substituents.
  • the most preferred cyclodextrin derivative for use in the compositions of the present invention is hydroxypropyl- ⁇ -cyclodextrin having a M.S. in the range of from 0.35 to 0.50 and containing less than 1.5% unsubstituted ⁇ -cyclodextrin.
  • M.S. values determined by NMR or IR preferably range from 0.55 to 0.75.
  • an intravenous (or intradermal) formulation preferably contains as few ingredients as possible. Therefore, a formulation without a solubilizer such as a cyclodextrin is preferred. Further, the neuroprotectant solution (a) preferably does not contain a preservative. Oral liquid formulations on the other hand can comprise both a solubilizer such as a cyclodextrin and one or more preservatives.
  • the present invention relates to neuroprotectant solutions (a) comprising: (i) 0.005 to 5% lubeluzole N-oxide or a pharmaceutically acceptable addition salt or a solvate thereof;
  • the invention relates to neuroprotectant solutions (a) comprising:
  • the invention relates to neuroprotectant solutions (a) containing approximately : (i) 0.05% lubeluzole N-oxide or a pharmaceutically acceptable addition salt or a solvate thereof; (ii) 5% glucose;
  • the solutions (a) are sterilized using art-known techniques.
  • the neuroprotectant solution (a) of the present product is conveniently used in the treatment of patients suffering from acute hypoxia.
  • an effective treatment for acute hypoxia involves administering to the patient by infusion an amount of lubeluzole N-oxide in the range of 10 to 30 ml of solution (a) or from 5 to 15 mg of the active ingredient during the first hour of therapy. During the following 24 hours about 4/3 or 133% of that amount may be administered. That is, one starts with a relatively high initial flow which is then lowered considerably. The maintenance dose may be administered for several consecutive days.
  • the effective amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compound of the instant invention.
  • the effective amount ranges mentioned hereinabove are therefore guidelines only and are not intended to limit the scope or use of the invention to any extent.
  • the lubeluzole N-oxide solutions may conveniently be co-administered with a physiological salt solution following to art-known infusion procedures. They may also be accompanied by administration of other anti-hypoxic drugs such as NMDA receptor antagonists, e.g. aptiganel, eliprodil, selfotel, tirilazad or remacemide; antithrombolytics, e.g. tPA, streptokinase, staphylokinase, heparin or similar agents.
  • NMDA receptor antagonists e.g. aptiganel, eliprodil, selfotel, tirilazad or remacemide
  • antithrombolytics e.g. tPA, streptokinase, staphylokinase, heparin or similar agents.
  • an infusion device or pack for the treatment of hypoxia comprising the product together with a disposable, independent drive unit is considered to be a most useful presentation of the product according to the present invention.
  • independent drive units for powering syringes in particular prefilled syringes, there may be named both gas-operated and vacuum-operated drive.
  • An interesting gas-operated intradermal drug delivery device permitting delivery of a drug at a slow rate which can be precisely controlled is described in WO-95/13838, corresponding to US-5,527,288.
  • the device comprises a housing with one or more drug reservoirs and a single hollow needle projecting outwards for a sufficient distance so as to penetrate through the stratum corneum and epidermis into the dermis when the housing is pressed against the skin.
  • the device can be of modular design consisting of disposable cartridge units comprising the depletable components (active ingredient, power source) and a reusable drive unit comprising amongst others the housing and the electronic controls.
  • the present invention evidently also concerns the use of a product as described hereinbefore for the preparation of a medicament for acute hypoxia treatment. Similarly, the present invention relates to a method of treating patients suffering from hypoxia, comprising administering to said patients a pharmaceutically effective amount of an N-oxide product as described hereinbefore.
  • Example 1 Preparation of (-)-[cis] lubeluzole N-oxide hemihydrate.
  • lubeluzole (11.6 g ; 27 mmol) in dichloromethane (700 ml), cooled to -10°C, was added m-chloroperbenzoic acid (6.7 g ; 31 mmol).
  • the reaction mixture was stirred for 24 hours, and then washed with an aqueous ammonia solution (2% ; 3 times) and water (3 times).
  • the organis phase was dried on MgSO 4 , filtered and evaporated, yielding 9.6 of raw material.
  • the product (-)-[cis] lubeluzole N-oxide hemihydrate was purified by recrystallization from methylisopropylketone
  • the useful anti-hypoxic properties of the product of the present invention can be demonstrated in the following test procedure.
  • placing scores are : 0, no placing; 1, incomplete and/or delayed placing; or 2, immediate, complete placing.
  • the summed tactile/proprioceptive placing score including the platform test, is maximally 10. Results are reported from the deficient hindlimb contralateral to the neocortical infarct. Six rats are used for each dose.
  • test animals receiving the lubeluzole N-oxide recover better from the induced stroke than those receiving lubeluzole itself.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention a pour objet un (des) N-oxyde(s) de lubeluzole, des compositions contenant ledit (lesdits) N-oxyde(s), des procédés de préparation de ces oxydes et leur utilisation en tant que médicament, en particulier dans le traitement d'états entraînant une hypoxie cérébrale.
PCT/EP1996/004608 1995-10-25 1996-10-21 N-oxyde de lubeluzole Ceased WO1997015572A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP9516279A JPH11513699A (ja) 1995-10-25 1996-10-21 ルベルゾールｎ−酸化物
EP96934801A EP0843674A1 (fr) 1995-10-25 1996-10-21 N-oxyde de lubeluzole
IL12308396A IL123083A0 (en) 1995-10-25 1996-10-21 Lubeluzole n-oxides their preparation and pharmaceutical compositions containing them
AU72982/96A AU7298296A (en) 1995-10-25 1996-10-21 Lubeluzole n-oxide
NO981687A NO981687D0 (no) 1995-10-25 1998-04-15 Lubeluzol N-oksid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95202887 1995-10-25
EP95202887.6 1995-10-25

Publications (1)

Publication Number Publication Date
WO1997015572A1 true WO1997015572A1 (fr) 1997-05-01

Family

ID=8220766

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/004608 Ceased WO1997015572A1 (fr) 1995-10-25 1996-10-21 N-oxyde de lubeluzole

Country Status (9)

Country Link
EP (1) EP0843674A1 (fr)
JP (1) JPH11513699A (fr)
CN (1) CN1200122A (fr)
AU (1) AU7298296A (fr)
CA (1) CA2228054A1 (fr)
IL (1) IL123083A0 (fr)
NO (1) NO981687D0 (fr)
WO (1) WO1997015572A1 (fr)
ZA (2) ZA968961B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544500B2 (en) 1999-11-13 2009-06-09 Talecris Biotherapeutics, Inc. Process for the production of a reversibly inactive acidified plasmin composition
US7871608B2 (en) 1999-11-13 2011-01-18 Talecris Biotherapeutics, Inc. Reversibly inactivated acidified plasmin
WO2014115745A1 (fr) 2013-01-23 2014-07-31 株式会社Adeka Agent antistatique, composition d'agent antistatique, composition de résine antistatique, et corps moulé
US9206410B2 (en) 2009-03-03 2015-12-08 Grifols Therapeutics Inc. Compositions, methods and kits for preparing plasminogen and plasmin prepared therefrom

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2078729A (en) * 1980-06-19 1982-01-13 Bristol Myers Co Encainide n-oxide
EP0184257A1 (fr) * 1984-12-03 1986-06-11 Janssen Pharmaceutica N.V. Dérivés de la benzoxazolamine et de la benzothiazolamine
EP0501552A1 (fr) * 1991-02-25 1992-09-02 Janssen Pharmaceutica N.V. 4-[(2-Benzothiazolyl)méthylamino]-alpha-[(3,4-difluorophénoxy)méthyl]-1-pipéridinéthanol

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2078729A (en) * 1980-06-19 1982-01-13 Bristol Myers Co Encainide n-oxide
EP0184257A1 (fr) * 1984-12-03 1986-06-11 Janssen Pharmaceutica N.V. Dérivés de la benzoxazolamine et de la benzothiazolamine
EP0501552A1 (fr) * 1991-02-25 1992-09-02 Janssen Pharmaceutica N.V. 4-[(2-Benzothiazolyl)méthylamino]-alpha-[(3,4-difluorophénoxy)méthyl]-1-pipéridinéthanol

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544500B2 (en) 1999-11-13 2009-06-09 Talecris Biotherapeutics, Inc. Process for the production of a reversibly inactive acidified plasmin composition
US7871608B2 (en) 1999-11-13 2011-01-18 Talecris Biotherapeutics, Inc. Reversibly inactivated acidified plasmin
US8268782B2 (en) 1999-11-13 2012-09-18 Grifols Therapeutics Inc. Composition and method for preparing plasminogen
EP1232251B2 (fr) † 1999-11-13 2017-05-17 Grifols Therapeutics Inc. Procede de thrombolyse par administration locale de plasmine acidifiee inactivee de maniere reversible
US9879246B2 (en) 1999-11-13 2018-01-30 Grifols Therapeutics Inc. Reversibly inactivated acidified plasmin composition
US9206410B2 (en) 2009-03-03 2015-12-08 Grifols Therapeutics Inc. Compositions, methods and kits for preparing plasminogen and plasmin prepared therefrom
WO2014115745A1 (fr) 2013-01-23 2014-07-31 株式会社Adeka Agent antistatique, composition d'agent antistatique, composition de résine antistatique, et corps moulé

Also Published As

Publication number Publication date
ZA968961B (en) 1998-04-24
JPH11513699A (ja) 1999-11-24
EP0843674A1 (fr) 1998-05-27
CN1200122A (zh) 1998-11-25
IL123083A0 (en) 1998-09-24
ZA968952B (en) 1998-04-24
AU7298296A (en) 1997-05-15
MX9803272A (es) 1998-09-30
NO981687L (no) 1998-04-15
NO981687D0 (no) 1998-04-15
CA2228054A1 (fr) 1997-05-01

Similar Documents

Publication Publication Date Title
JP5227029B2 (ja) デシタビン医薬製剤
JP6378408B2 (ja) マクロライド抗生物質を投与するための非経口製剤
JP2015503635A (ja) フマギリン誘導体ｐｈｆ複合体の医薬品配合物
US20090291913A1 (en) FACTOR Xa INHIBITOR FORMULATION AND METHOD
BR122020021551B1 (pt) Composição farmacêutica antimicrobiana e seu uso
US20030032664A1 (en) Method of cancer treatment
RU2531350C2 (ru) Соединение, обладающее сокращающей детрузор активностью и релаксирующей уретральный сфинктер активностью
WO1997015572A1 (fr) N-oxyde de lubeluzole
JP6860677B2 (ja) グローコカリキシンａ誘導体、その医薬的に許容できる塩または医薬組成物、およびこれらの乾癬治療用医薬の調製における使用
WO1997015306A1 (fr) Perfusions de neuroprotecteurs et d'agents chimiques perfluores
WO1997015323A1 (fr) Perfusions de neuroprotecteurs et d'agents thrombolytiques
RU2337685C2 (ru) Антагонисты нейрокининового рецептора nk-1 для выхода из наркоза
MXPA98003272A (en) N-oxido de lubelo
KR0148224B1 (ko) 진양조성물
JP2961093B2 (ja) 関節疾患治療用のカルボキサミドの安定で長時間作用型の塩
EP4112608A1 (fr) Composé d'isosélénazole à fusion aryle contenant un substituant de tétrazine, son procédé de synthèse et son utilisation
WO2014201312A1 (fr) Nanoparticules pour l'encapsulation et la délivrance de composés bioactif et compositions de celles-ci
KR20110084514A (ko) 피리딘-3-카르발데히드 ｏ-(피페리딘-1-일-프로필)-옥심 유도체를 유효 성분으로서 함유하는 망맥락막 변성 질환의 치료제
WO2000056336A2 (fr) Compositions pharmaceutiques contenant un derive de pyrimidine et de la cyclodextrine
JPS61129124A (ja) 抗腫瘍剤
WO2025162314A1 (fr) Composition pharmaceutique contenant un inhibiteur de prmt5 et un inhibiteur de pd-1/pd-l1
JPH10509712A (ja) ルベルゾール静脈用水剤
CN118436762A (zh) 替考拉宁在制备治疗雄激素性脱发药物中的应用
JP2008509141A (ja) 非経口製剤の組織刺激を軽減させる方法及び組成物
JPH01233282A (ja) １，３，４−チアジアゾール誘導体及びそれを有効成分として含有する抗潰瘍剤

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96197774.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU BB BG BR CA CN CZ EE GE HU IL IS JP KG KR LK LR LT LV MD MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996934801

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2228054

Country of ref document: CA

Ref document number: 2228054

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 320274

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 1997 516279

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/003272

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 1996934801

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996934801

Country of ref document: EP